Literature DB >> 15570187

Association between patient age and gabapentin serum concentration-to-dose ratio: a preliminary multivariate analysis.

Juan A Armijo1, María A Pena, Javier Adín, Noelia Vega-Gil.   

Abstract

OBJECTIVES: To evaluate the association between patient age and gabapentin (GBP) concentration-to-dose ratio by a multivariate analysis.
METHODS: The association between patient age and the trough steady-state serum concentration of gabapentin (GBP) normalized to 1 mg/kg body weight or concentration-to-dose ratio (CDR) was retrospectively assessed by analysis of covariance. Potential confounding factors considered were GBP dosage, the number of GBP doses per day, and the presence of concomitant antiepileptic drugs (AEDs). Concentrations that had been measured in predose "trough" samples collected from 66 patients, aged 5-84 years, with partial seizures or neuropathic pain chronically receiving GBP BID (n = 21) or TID (n = 45), alone (n = 15) or in combination with other AEDs (n = 51) were used in this retrospective analysis.
RESULTS: Average GBP CDR was 0.23 +/- 0.18 (mean +/- SD). The GBP CDR increased with age (r2 = 0.46, P < 0.001), and the correlation was improved when only samples from patients taking GBP BID were separately considered (r2 = 0.68, P < 0.001). The ratio was lower in the 10 children younger than 11 years of age (0.07 +/- 0.05) than in 8 adolescents aged 12 to 18 years (0.14 +/- 0.04), lower than in 35 adults aged 19 to 65 years (0.22 +/- 0.13), and lower than in 13 patients older than 65 years of age (0.45 +/- 0.20) by 1-way analysis of variance (F = 19.4, P < 0.001). Analysis of covariance showed a significant influence on GBP CDR of patient age (P < 0.001) and the number of GBP daily doses (P < 0.01), but GBP daily dosage or concomitant AEDs had no significant influence on the ratio.
CONCLUSIONS: In this retrospective study of a small, select group of patients, (1) the GBP CDR increased significantly with age when potential confounding factors such as GBP dosage, number of GBP doses per day, and concomitant AEDs were considered by analysis of covariance, and (2) patients older than 65 years, even without any known renal disease, may have double GBP CDR than younger adults and, therefore, may need half of the GBP dose per body weight to achieve a similar concentration.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15570187     DOI: 10.1097/00007691-200412000-00008

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  12 in total

Review 1.  Management of focal-onset seizures: an update on drug treatment.

Authors:  Svein I Johannessen; Elinor Ben-Menachem
Journal:  Drugs       Date:  2006       Impact factor: 9.546

2.  Gabapentin-induced severe myoclonus in a patient with impaired renal function.

Authors:  Martin Holtkamp; Annett Halle; Hartmut Meierkord; Florian Masuhr
Journal:  J Neurol       Date:  2005-08-25       Impact factor: 4.849

3.  Effectiveness of preanesthetic administration of gabapentin on sedative action during intravenous sedation with propofol.

Authors:  Rumiko Hosokawa; Shinichi Ito; Jun Hirokawa; Yu Oshima; Takeshi Yokoyama
Journal:  J Anesth       Date:  2018-09-20       Impact factor: 2.078

4.  Pharmacokinetics and Saturable Absorption of Gabapentin in Nursing Home Elderly Patients.

Authors:  Ghada F Ahmed; Sai Praneeth R Bathena; Richard C Brundage; Ilo E Leppik; Jeannine M Conway; Janice B Schwartz; Angela K Birnbaum
Journal:  AAPS J       Date:  2017-01-09       Impact factor: 4.009

Review 5.  Pharmacokinetic variability of newer antiepileptic drugs: when is monitoring needed?

Authors:  Svein I Johannessen; Torbjörn Tomson
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

6.  Modern methods for analysis of antiepileptic drugs in the biological fluids for pharmacokinetics, bioequivalence and therapeutic drug monitoring.

Authors:  Juseop Kang; Yoo-Sin Park; Shin-Hee Kim; Sang-Hyun Kim; Min-Young Jun
Journal:  Korean J Physiol Pharmacol       Date:  2011-04-30       Impact factor: 2.016

Review 7.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age.

Authors:  Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

8.  Therapeutic Drug Monitoring of the Newer Anti-Epilepsy Medications.

Authors:  Matthew D Krasowski
Journal:  Pharmaceuticals (Basel)       Date:  2010-06-11

9.  Pharmacokinetic Factors to Consider in the Selection of Antiseizure Drugs for Older Patients with Epilepsy.

Authors:  Gail D Anderson; Shahin Hakimian
Journal:  Drugs Aging       Date:  2018-08       Impact factor: 3.923

Review 10.  Clinical pharmacokinetics of new-generation antiepileptic drugs at the extremes of age: an update.

Authors:  Domenico Italiano; Emilio Perucca
Journal:  Clin Pharmacokinet       Date:  2013-08       Impact factor: 6.447

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.